UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007120
Receipt number R000008384
Scientific Title A Prospective Single-center dose escalation study on the Safety of Lactoferin for post-treated advanced & recurrent non-small cell lung cancer
Date of disclosure of the study information 2012/01/23
Last modified on 2013/11/18 12:50:03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Prospective Single-center dose escalation study on the Safety of Lactoferin for post-treated advanced & recurrent non-small cell lung cancer

Acronym

A Prospective Single-center dose escalation study on the Safety of Lactoferin for post-treated advanced & recurrent non-small cell lung cancer

Scientific Title

A Prospective Single-center dose escalation study on the Safety of Lactoferin for post-treated advanced & recurrent non-small cell lung cancer

Scientific Title:Acronym

A Prospective Single-center dose escalation study on the Safety of Lactoferin for post-treated advanced & recurrent non-small cell lung cancer

Region

Japan


Condition

Condition

Non-small cell lung cancer

Classification by specialty

Pneumology Chest surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To determine the recommended dose (RD) of TS-1 and Lactoferin

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase I


Assessment

Primary outcomes

RD : Recommended Dose

Key secondary outcomes

Safety,Efficacy,Immunological response,QOL


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine Food

Interventions/Control_1

1)lactferin is administered orally.
Level 1 lactoferin 1g/day
Level 2 lactoferin 2g/day
Level 3 lactoferin 3g/day
2)TS-1 80mg/m2/day is administered orally for 2 consecutive weeks every 3 weeks.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

84 years-old >=

Gender

Male and Female

Key inclusion criteria

1)histologically or cytologically confirmed unresectable non-small cell lung cancer, previous 2- regimen chemotherapy
2)Presence of at least one measurable lesion
3)ECOG Performance status 0-2
4)Life expectancy more than 3 months
5)Age: 20-84 years old
6)preserved organ's function
Hb>=9g/d
WBC>=3,000/mm3
Neutro>=1,500/mm3
Plt>=100,000/mm3
Total serum bilirubin <=1.5 mg/dl
GOT/GPT,ALP <=2xULNmg/dl
Serum creatinine <=1xULNmg/dl
Ccr>=50ml/min
7)Acquisition of written informed consent

Key exclusion criteria

1)pulmonary fibrosis or interstitial pneumonitis evident
2)Massive pleural effusion, pericardial effusion,and abdominal effusion
3)Simultaneous or metachronous double cancers
4)serious complications below
a)myocardial infarction within 6 months
b)Uncontrolled diabetes or hypertension
c)Current severe infection, or suspicious of severe
infection
d)History of serious drug allergic reaction
e)Massive effusion or edema
f)Patients whose participation in the trial is judged to be inappropriate by the attending doctor
5)Symptomatic brain metastasis
6)now pregnant or lactation
7)History of radiation therapy or operation for lung cancer within 28 days at the time of entry.
8)History of unapproved drugs within 28 days at the time of entry.
9)Participation in this study before
10)History of serious allergic reaction with S-1
11)Being treated with other pyrimidine fluoride antineoplastic agents.
12)Being treated with flucytosine.
13)Wattery diarrhea
14)lactose intolerance
15)difficult to perform or continue of this study

Target sample size

18


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masahiro Tsuboi

Organization

Kanagawa Cancer Center

Division name

Department of Thoracic Oncology

Zip code


Address

1-1-2, Nakao, Asahi-ku, Yokohama, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Kanagawa Cancer Center

Division name

Department of Thoracic Oncology

Zip code


Address


TEL


Homepage URL


Email



Sponsor or person

Institute

Kanagawa Cancer Center

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 01 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2011 Year 07 Month 10 Day

Date of IRB


Anticipated trial start date

2012 Year 01 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 01 Month 23 Day

Last modified on

2013 Year 11 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008384


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name